Stavropol, Irkutsk, Nizhny Novgorod ("ImBio"), Moscow, Tomsk ("Virion"), Perm ("Biomed") and Ufa ("Immunopreparat"). The company has a staff of more than 6,000 people. Production The company produces more than 70% of the total Russian immunobiological products, including two of the four vaccines against A/H1N1. Microgen also has a monopoly on the production of a number of other vaccines. In 2013, the company controlled 23% of the Russian market of medicines from donated blood plasma. The company supplies 70% of vaccines and toxoids included in the National Immunisation Calendar of Russia. Microgen produces a range of over 120 immunobiological products: vaccines, sera, specific and polyvalent immunoglobulins, nutrient medium, allergens, probiotics etc. Of these, 60 products are included in the Russian list of vital and essential medicines. Microgen is the only enterprise in Russia producing bacteriophages on an industrial scale. Its medical drugs and products are exported to Kazakhstan, Ukraine, Belarus, Uzbekistan, Azerbaijan, Armenia, Georgia, Mexico, Mongolia, Vietnam and India. Research The company is developing more than 15 products, including a new version of influenza vaccine, tissue culture vaccines against varicella, rabies, tick-borne encephalitis, combined vaccines DTP-HepB-Hib, HepB-aDTP-Hib and MMR (measles, mumps and rubella) and complex preparations of bacteriophages, etc. Microgen is involved in several international research projects, including the WHO program to combat smallpox, measles, rubella, tuberculosis, avian influenza, etc. Since 2013, Microgen has been involved in the development of a new drug for the treatment of leukaemia and other antitumor drugs. In 2014, the company announced the launch of clinical trials of the drug "Relatoks" (botulinum toxin type A – haemagglutinin complex) in paediatric neurology The research projects of the company involve over 130 PhD Candidates and more than 30 Doctors of Science. Microgen is among the ten most innovative companies in Russia, according to RBC Group ratings. Finance The company's 2013 revenue amounted to RUB 7.6 bln., net profit - RUB 1 bln. In 2012, the company was the fifth largest in terms of revenue among all Russian pharmaceutical manufacturers. On the basis of 2012 results, the DSM Group analysts estimated the company's overall turnover at RUB 5.1 bln. One of the company's branches ("Virion", Tomsk) in 2013 supplied RUB 950 mln. worth of products. In 2012 the company completed 43 State contracts, totalling more than RUB 1.8 bln. In 2011, revenues from exports reached RUB 500 mln. The same year, Microgen has spent close to RUB 2 bln.